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incidence
The yearly incidence of the acute myeloblastic leukaemias
(AMLs) in European adults is 5–8 cases per 100 000
individuals, and in myelodysplastic syndromes (MDSs) 4–5
new cases/100 000 are expected yearly. In individuals >60 years
incidences of both AMLs and MDSs increase significantly,
reaching 40–60 new cases of MDS per 100 000/year. Yearly
mortality figures are 4–6 cases per 100 000 in AMLs and
somewhat higher for MDSs.
diagnosis
The diagnosis of both AMLs and MDSs requires the
examination of peripheral blood and bone marrow specimens.
The work-up of these specimens should include morphology,
cytochemistry, immunophenotyping (more important in AMLs
than in MDSs), cytogenetics and molecular genetics.
Whilst historically classified by the largely descriptive
French–American–British (FAB) criteria, myeloid neoplasms
including MDSs and AMsL are now classified according to the
WHO classification from 2001, revised in 2008. The WHO
classification now incorporates, in addition to morphological
criteria, genetics, immunophenotype data and clinical
information into a diagnostic algorithm to delineate clinically
significant disease entities. In the WHO classification the term
‘myeloid’ includes all cells belonging to the granulocytic,
monocyte/macrophage, erythroid, megakaryocytic and mast
cell lineages. The percentage of blast cells in the bone marrow is
a practical tool for categorizing myeloid neoplasms into AML
or MDS, respectively, where myeloid neoplasms with >20%
blasts in the peripheral blood or bone marrow are considered
AMLs, either de novo, or having evolved from a pre-existing
MDS. Blasts are defined using the criteria recently proposed by
the International Working Group on Morphology of MDS. In
contrast to a diagnosis of AML, MDSs remain a considerable
diagnostic challenge, particularly in cases where blast counts are
not increased in the bone marrow, and morphological findings
are inconclusive. The ‘minimal’ diagnostic criteria for MDSs
include the appropriate clinical setting, unequivocal dysplasia
of ‡10% of cells from at least one myeloid lineage in the bone
marrow, and causes of secondary dysplasia must be excluded. If
morphological features are inclonclusive, a diagnosis of MDS
can still be made if one or several specific clonal chromosomal
abnormalities are found on cytogenetics. In the absence of
morphological and/or cytogenetic findings suggestive of MDS,
flow cytometry abnormalities are not diagnostic of MDS. In
uncertain cases, careful follow-up investigations (chiefly
morphology and karyotyping) are recommended at regular
intervals of at least several months.
risk assessment and prognostic factors
Patient age, initial leukocyte counts (in AMLs) and
co-morbidity are important risk factors, but prognosis is chiefly
governed by AML and MDS subtypes or entities. Morphology
is still a particularly important tool to classify MDSs, defining
such categories as the refractory anaemias with or without ring
sideroblasts, or refractory cytopenia with multilineage
dysplasia. AMLs having evolved from previously documented
MDS generally have an adverse prognosis. Nowadays,
molecular and genetic risk stratification have become the key
principles to guide the therapy of both MDSs and AMLs.
karyotype/cytogenetics
AMLs with the chromosomal translocations t(15;17)(q22;q12),
i.e. acute promyelocytic leukaemia (APL), t(8;21)(q22;q22),
and inv(16)(p13.1q22), or t(16;16)(p13.1;q22) (mostly
myelomonocytic leukaemia with preponderance of eosinophil
granulocytes in the bone marrow) are the most favourable types
of AML. Patients with normal karyotype AMLs are in an
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intermediate-risk group, and AMLs with complex karyotype
abnormalities, and/or chromosomal monosomies fare
particularly poorly.
In the MDSs, patients with partial deletion of genetic
material from chromosome 5q (5q syndrome) or deletion of
the Y chromosome are considered to be the most favourable
category, and patients with MDS harbouring complex
karyotype abnormalities, and/or chromosomal monosomies
other than the 5q or –Y syndromes fare the worst. In MDSs
a commonly used prognostic tool is the International
Prognostic Scoring System (IPSS), recently modified to yield
the World Prognostic Scoring System (WPSS), which in
addition to blast percentage and cytogenetics also considers
transfusion requirements in cytopenic patients. However, other
systems have been or are being developed to improve
prognostic scoring in MDSs.
molecular genetics
Good-risk translocations in AMLs defined above are all
amenable to detection with molecular techniques (PCR or
FISH) which may be faster than classical cytogenetics, and are
therefore recommended. In cytogenetically normal AMLs,
somatic mutations of the genes FLT3, NPM1 or CEBPa have
been identified as important prognostic factors. NPM1 and
CEBPa mutations are favourable when present as single
mutations, whereas FLT3 alterations are not, irrespective of
whether they occur on their own, in combination with NPM1
and CEBPa mutations, or with any karyotype alterations.
Patients with abnormalities of the chromosomal region 11q23
representing the MLL (Mixed Lineage Leukaemia gene) fare
poorly. Gene expression profiles assessed by microarray
technology have been reported to split both AMLs and MDSs
into defined sub-/categories, but these techniques are not yet
ready for widespread routine use.
co-morbidity and other host factors
Patients aged ‡60–65 years are more susceptible to treatment
complications than younger patients, which contributes to their
higher risk of an unfavourable outcome. Pre-existing medical
conditions such as diabetes, coronary heart disease or chronic
pulmonary obstructive disease must also be recognized as
contributing to poor risk. To assess cardiac risk factors at
diagnosis, in addition to clinical examination, cardiac
echocardiography is recommended.
At diagnosis, patients should be investigated for the presence
of active infection, particularly those planned for intensive
treatment. In addition to clinical examination, additional
techniques recommended are CT scans of the chest and
abdomen, and radiological imaging of teeth and jaws to identify
infectious foci such as dental root granulomas and caries. In
addition to haematological and chemistry laboratory tests,
a coagulation status must be obtained to detect leukaemia-
related coagulopathy, particularly in APL; such tests must be
performed before the insertion of central intravenous lines.
other pre-treatment investigations
Patients potentially suitable for allogeneic stem cell
transplantation should be HLA typed at diagnosis, as should
their available first-degree family members. In high-risk disease
(e.g. poor karyotype), early matched unrelated donor (MUD)
allogeneic transplantation must be considered, and therefore,
a donor search should be performed as early as possible.
treatment
Whenever possible, leukaemia treatment should be offered in
clinical trials, and conducted only in experienced centres
offering an adequate multidisciplinary infrastructure as well as
a suitably high case load. In AMLs treatment should be planned
with curative intent whenever possible, whilst in patients with
MDS the goal of cure cannot often be reached. In contrast to
AMLs, allogeneic stem cell transplantation (alloSCT) is the only
curative treatment in MDSs, whereas a sizeable proportion of
AML patients can be offered curative chances without alloSCT.
Intensive treatment in AMLs and in selected patients with MDS
suitable for this approach, is divided into an induction phase,
consolidation and (rarely) maintenance chemotherapy.
Potential AML or MDS candidates for alloSCT (scheduled for
the consolidtion phase) must be identified early at diagnosis or
during induction chemotherapy.
intensive treatment of AMLs and MDSs
Induction chemotherapy should only be started (if possible)
when all material needed for diagnostic tests has been
satisfactorily sampled. Patients with excessive leukocytosis at
presentation may require emergency leukapheresis before
commencing chemotherapy.
Induction chemotherapy should include an anthracycline
and cytosine arabinoside, with the ‘3+7’ regimen particularly
well known. APL induction chemotherapy consists of all-trans
retinoic acid (ATRA) as a differentiating agent and an
anthracycline, but the role of cytarabine in the treatment of
APL is controversial. These patients must be followed very
closely for the development of leukaemia-associated
coagulopathy. Haematopoietic growth factors are an optional
adjunct to intensive induction chemotherapy, and their role in
priming leukaemic cells to become more sensitive to the
cytostatic agents during induction remains to be confirmed.
Consolidation therapy in AML and MDS is warranted once
patients have reached clinical and haematological remission.
There is no consensus on a single ‘best’ post-remission
treatment schedule. Patients who are unsuitable for alloSCT
should receive intensive consolidation chemotherapy,
preferably incorporating high-dose cytarabine into the
consolidation regimen. In good-risk patients, who have
a relapse risk of £35%, alloSCT is not justified in first remission
because the risk of toxicity and/or transplantation-related
mortality exceeds the benefit. Patients with AML in
intermediate- and poor-risk groups, as well as higher-risk MDS
patients with an HLA-identical sibling are candidates for
alloSCT, provided their age and performance status allow for
such treatment. Patients in these risk groups without a family
donor may qualify for alloSCT with an HLA-matched unrelated
donor identified through an international donor registry. If
a killer-immunoglobulin-like receptor (KIR) mismatch is
present, haploidentical transplants may be considered.
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Conditioning regimens with dose-reduced intensity may be
used for patients in the upper age range (particularly those >50
years of age). Infectious disease complications contracted
during induction should be under suitable control before an
alloSCT is enacted. The role of high-dose chemotherapy with
autologous stem cell retransfusion in AMLs or MDSs is still
controversial. Whilst it may prolong time to relapse or
remission duration, its potential to prolong overall survival is
uncertain. Maintenance therapy has been firmly established for
first-remission APL only, where a combination of long-term
chemotherapy and ATRA is warranted.
non-intensive treatment of MDS and AML
Patients with significant co-morbidity, the elderly, thus
including many patients with MDS, are often not eligible for
intensive treatment, and they should receive best supportive
care (BSC) or palliative systemic treatment. Excessive
leukocytosis due to spilling of malignant blasts into the
periphery may be reduced with cytoreductive agents such as
hydroxyurea or low-dose cytarabine, drugs that also reduce
normal blood cells such as red cells, neutrophils or platelets. In
BSC, treatment of infections due to neutropenia and
transfusions to cover anaemia or thrombocytopenia are
important measures for both AMLs and MDSs. Erythroid and
myeloid growth factors are commonly used as part of
supportive measures in MDSs, but their effect on the natural
history is ill known.
In MDSs with low cell counts in the bone marrow
(hypoplastic MDS) immunomodulatory treatment (similar to
aplastic anaemia) may be offered, e.g. antithymocyte globulin,
with limited success. MDS patients with the 5q syndrome may
be treated with lenalidomide which obtains cytogenetic
responses in half of them, and significantly reduces their red
cell transfusion requirements. MDS patients may also be
candidates for treatment with drugs inhibiting DNA
methyltransferase (e.g. 5-azacytidine, or 5-aza-2’-
deoxycytidine/decitabine). Randomized comparisons of 5-
azacytidine against low-dose cytarabine or BSC have shown
some survival benefit, particularly for patients with
chromosome 7 alterations, whilst trials comparing decitabine
with BSC have been negative in this respect.
therapy of refractory or relapsed AML or MDS
Patients failing to respond to one or two cycles of induction
treatment are considered refractory, and are at very high risk of
ultimate treatment failure. Carefully selected patients with an
HLA-matched donor may be offered alloSCT, albeit with very
limited chances of success, and at the cost of considerable
morbidity from this procedure. For patients unsuited to this
approach, BSC or palliative systemic treatment is often
a reasonable option with at least limited toxicity. The prognosis
of such patients is often dismal regardless of treatment
attempts.
Patients presenting with relapse after a first remission may be
offered intensive re-induction, where chances of success are
better after longer duration of first remission. Patients in
second or subsequent remission may still qualify for alloSCT
with a family or unrelated HLA-matched donor. In relapsed
APL, arsenic trioxide can induce remissions, even in patients
who have turned refractory to ATRA. The role of arsenic
trioxide in first line therapy of APL, however, is not yet clearly
settled.
response evaluation and follow-up
Response of AML or MDS to treatment is monitored clinically,
with serial peripheral blood counts and repeat bone marrow
examinations. During intensive chemotherapy, bone marrow
should be examined in the aplastic phase to monitor blast
clearance, persistence or early relapse. The usually accepted
criteria of response in AMLs and MDSs are blast clearance in
the bone marrow to <5% of all nucleated cells, morphologically
normal haematopoiesis and return of peripheral blood cell
counts to normal levels. Clearance of infections contracted
during therapy-induced aplasia should also be documented.
Patients having concluded treatment should be followed
clinically and with repeated haematological examinations.
Serial bone marrow examinations of patients in remission are
of uncertain value, and cannot therefore be generally
recommended. Although sensitive PCR methods are available
permitting molecular follow-up for patients with suitable
markers (mostly specific chromosomal translocations), the
early detection of molecular relapse in the absence of
morphological evidence for recurrent leukaemia or MDS is of
uncertain therapeutic consequence. Specifically evidence that
early reinduction treatment of such patients still in
haematological remission would be of any benefit is lacking.
note
Levels of Evidence (I–V) and Grades of Recommendation
(A–D) are used as recommended by the American Society of
Clinical Oncology. Statements in the text that were not graded,
were considered otherwise justified clinical practice by the
experts and reviewers, and the ESMO faculty.
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